3Lai CL, Gane E, Laiw YF, et al. Telbivudine (LdT) vs. lamivudine for chronic hepatitis B : first - year results from the international phase Ⅲ globe trial . Hepatology,2005,42:748A.
4Lai CL, Gane E, Laiw YF, et al. Two- year results from the GLOBE trial in patients with hepatitis with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs lamivudihe. Hepatology ,2006,44:222A. Abstact 91.
5DiBisceglie A,Lai CL ,Gane E, et al. Telbivudine GLOBE trial: Maximal early HBV suppression is predictive of optimal two - year efficacy in nucleoside treated hepatitis B patients. Hepatology, 2006,44 :230A. Abstract 112.
6Keeffe E,Zeuzem S,Koff ll,et al. Report of an international workshop :roadmap for management of patient reeiving oral therapy for zehronie hepatitis B. Clin Gastroenterol Hepatol, 2007,5 : 890 - 897.
9Zhou X J, Lloyd DM,Chao GC, et al. Absence of food effect on the pharmcokinetics of telbivudine following oral administration in healthy subjects. J Clin Pharmacol ,2006 ,46 :275 - 281.
2Bryant ML,Bridges EG,Placidi L,et al.Amiviral L-nucleosides specific for hepatitis B virus infection.Antimicrob Agents Chemother,2001,45:229-235.
3Standring DN,Bridges ED,Placidi L,et al.Antiviral β-L-nucleosides specific for hepatitis B virus infection.Antiviral Chemist Chemother,2001,12:119-129.
4Zhou XJ,Lim SG,Lloyd DM,et al.Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection:pharmacodynamic implications.Antimicrob Agents Chemother,2006,50:874-879.
5Zhou XJ,Lloyd DM,Chao GC,et al.Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects.J Clin Pharmacol,2006,46:275-281.
6Lai CL,Lim SG,Brown NA,et al.A dose finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection.Hepatology,2004,40:719-726.
7Lai CL,Leung N,Teo EK,et al.A 1-year trial of telbivudine,lamivudine,and the combination in patients with hepatitis B e antigenpositive chronic hepatitis B.Gastroenterology,2005,129:528-36.
8Lai CL,Gane E,Liaw YF,et al.Telbivudine (LdT) vs.lamivudine for chronic hepatitis B:first-year results from the international phase Ⅲ globe trial.Hepatology,2005,42:748A.
9Lai CL,Gane E,Hsu CW,et al.Two-year results from the GLOBE trial in patients with hepatitis B:greater clinical and antiviral efficacy for telbivudine (LdT) vs Lamivudine.Hepatology,2006,44:222A.Abstact 91.
10Poynard T,Chutaputti A,Hwang S G,et al.Sustained off-treatment HBeAg response in telbivudine and lamivudine treated HBeAg-positive patients from the GLOBE study.J Hepatol,2006,46:S27.Abstract 58.
8Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
